Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rebecca Roedersheimer

Urology Cincinnati, OH Medical Doctor

NPI 1538388848 CMS profile 341692

3301 Mercy Health Blvd, Suite 525, Cincinnati, OH 45211

Open in the dashboard

General payments

$13,902

621 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rebecca Roedersheimer of Cincinnati, OH is reported in the CMS Open Payments database as having received $13,902 across 621 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,062 83
2024 General $2,388 109
2023 General $3,737 127
2022 General $1,558 104
2021 General $2,119 85
2020 General $946 58
2019 General $1,093 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rebecca Roedersheimer
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Rebecca Roedersheimer were reported at $2,062. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Rebecca Roedersheimer Urology median Middle half National median
2019 $1,093 $480 $147–$1,201 $163
2020 $946 $246 $87–$645 $114
2021 $2,119 $358 $111–$1,000 $132
2022 $1,558 $476 $143–$1,263 $149
2023 $3,737 $560 $168–$1,461 $160
2024 $2,388 $563 $170–$1,464 $164
2025 $2,062 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Coloplast Corp $2,364 80 payments
  2. Axonics Modulation Technologies, Inc. $1,867 72 payments
  3. Astellas Pharma US Inc $1,337 77 payments
  4. Medtronic, Inc. $1,311 53 payments
  5. AbbVie, Inc. $972 61 payments
  6. Boston Scientific Corporation $603 25 payments
  7. Teleflex LLC $552 7 payments
  8. Sumitomo Pharma America, Inc. $539 27 payments
  9. Medtronic USA, Inc. $481 33 payments
  10. Urogen Pharma, Inc. $468 24 payments
  11. Other $3,407 162 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,466 590 payments
  2. Travel and Lodging $1,863 8 payments
  3. Education $449 22 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $124 1 payment
Products named General payments · program years 2019–2025
  1. INTERSTIM Sacral Nerve Stimulation $1,311 53 payments
  2. Axonics $955 54 payments
  3. MYRBETRIQ $949 61 payments
  4. Axonics r-SNM System $820 10 payments
  5. Bulkamid $797 7 payments
  6. BOTOX $744 46 payments
  7. SpeediCath $559 47 payments
  8. GEMTESA $551 32 payments
  9. INTERSTIM Sacral Nerve Stimulation $481 33 payments
  10. JELMYTO $468 24 payments
  11. Other $6,283 297 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

2,860

Median for Urology: 1,053

Drug cost

$742,316

Median for Urology: $101,464

Branded share of claims

54.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 505 $371,208
Gemtesa Vibegron Brand 381 $296,821
Mirabegron Er Mirabegron Brand 27 $19,820
Estradiol Generic 282 $18,213
Trimethoprim Generic 104 $4,817
Potassium Citrate Er Potassium Citrate Brand 34 $4,193
Methenamine Hippurate Generic 71 $3,621
Solifenacin Succinate Generic 37 $2,734
Cephalexin Generic 291 $2,655
Fosfomycin Tromethamine Generic 15 $2,535

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 111 billing codes

Paid by Medicare

$271,601

Of which drugs: $73,941

Medicare patients

728

Average age 76

Services billed

12,581

528 women, 200 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Depression 30%
Diabetes 29%
Ischemic heart disease 28%
Chronic kidney disease 28%
Osteoporosis 24%
Cancer 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Bcg live intravesical instillation, 1 mg J9030 Office 27 3,800 $8,430
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 21 2,100 $218

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
$500 — —
GEMTESA
$233 381 —
PROVENGE
$133 — —
JELMYTO
$114 — —
ERLEADA
$93 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

621 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record